Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?

Diabetes and Metabolism

Volumn 44, Issue 3, 2018, Pages 217-225

  Leggio, M ^a   Bendini, M G ^b   Caldarone, E ^c   Lombardi, M ^c   Severi, P ^a,c   D'Emidio, S ^c   Stavri, D C ^c   Armeni, M ^d   Bravi, V ^e   Mazza, A ^b  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b Santa Maria della Stella Hospital   (Italy)

^c Salus Infirmorum Clinic   (Italy)

^d Istituti Fisioterapici Ospitalieri Rome   (Italy)

^e Still osteopathic institute   (Italy)

Author keywords

Cardiovascular disease; Diabetes mellitus; Low dose aspirin; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; FIBRINOLYTIC AGENT;

BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; PRACTICE GUIDELINE; REVIEW; THROMBOCYTE; DIABETIC COMPLICATION; PRIMARY PREVENTION; RISK FACTOR;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FIBRINOLYTIC AGENTS; HUMANS; PRIMARY PREVENTION; RISK FACTORS;

EID: 85035112214     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2017.11.002     Document Type: Review

References (96)

1. Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
2. Ferreiro, J.L., Angiolillo, D.J., Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123 (2011), 798–813.
3. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
4. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998), 229–234.
5. American Diabetes Association, 8: cardiovascular disease and risk management. Diabetes Care 39:Suppl. 1 (2016), S60–S71.
6. Davì G., Catalano, I., Averna, M., Notarbartolo, A., Strano, A., Ciabattoni, G., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322 (1990), 1769–1774.
7. Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002), 2570–2581.
8. American Diabetes Association, Aspirin therapy in diabetes. Diabetes Care 26:Suppl. 1 (2003), S87–S88.
9. IDF Clinical Guidelines Task Force, Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 23 (2006), 579–593.
10. Buse, J.B., Ginsberg, H.N., Bakris, G.L., Clark, N.G., Costa, F., Eckel, R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007), 114–126.
11. Steering Committee of the Physicians’ Health Study Research Group, Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321 (1989), 129–135.
12. de Gaetano, G., Collaborative Group of the Primary Prevention Project, Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice: Collaborative Group of the Primary Prevention Project. Lancet 357 (2001), 89–95.
13. Ridker, P.M., Cook, N.R., Lee, I.M., Gordon, D., Gaziano, J.M., Manson, J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005), 1293–1304.
14. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 351 (1998), 1755–1762.
15. Antithrombotic Trialists’ Collaboration, Cllaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
16. Brun, E., Nelson, R.G., Bennett, P.H., Imperatore, G., Zoppini, G., Verlato, G., et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 23 (2000), 1119–1123.
17. Roper, N.A., Bilous, R.W., Kelly, W.F., Unwin, N.C., Connolly, V.M., Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care 25 (2002), 43–48.
18. Antithrombotic Trialists’ (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
19. JCS Joint Working Group, Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J 77 (2013), 231–248.
20. De Berardis, G., Sacco, M., Strippoli, G.F., Pellegrini, F., Graziano, G., Tognoni, G., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 339, 2009, b4531.
21. Calvin, A.D., Aggarwal, N.R., Murad, M.H., Shi, Q., Elamin, M.B., Geske, J.B., et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 32 (2009), 2300–2306.
22. Pignone, M., Williams, C.D., Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol 6 (2010), 619–628.
23. Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E., Mukherjee, D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 121 (2010), 2694–2701.
24. Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E., Mukherjee, D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 33 (2010), 1395–1402.
25. Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E., Mukherjee, D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 55 (2010), 2878–2886.
26. Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33 (2012), 1635–1701.
27. Patrono, C., García Rodríguez, L.A., Landolfi, R., Baigent, C., Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005), 2373–2383.
28. Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 (2004), 784–794.
29. Lanas, A., Bajador, E., Serrano, P., Fuentes, J., Carreño, S., Guardia, J., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000), 834–839.
30. Bhatt, D.L., Cryer, B.L., Contant, C.F., Cohen, M., Lanas, A., Schnitzer, T.J., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
31. Gargiulo, G., Capodanno, D., Longo, G., Capranzano, P., Tamburino, C., Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther 12 (2014), 1185–1203.
32. Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001), 1809–1817.
33. Schjerning Olsen, A.M., Gislason, G.H., McGettigan, P., Fosbøl, E., Sørensen, R., Hansen, M.L., et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 313 (2015), 805–814.
34. Grosser, T., Fries, S., Lawson, J.A., Kapoor, S.C., Grant, G.R., FitzGerald, G.A., Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 127 (2013), 377–385.
35. Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 53 (2009), 667–677.
36. Angiolillo, D.J., Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 103 (2009), 27A–34A.
37. Michelson, A.D., Cattaneo, M., Eikelboom, J.W., Gurbel, P., Kottke-Marchant, K., Kunicki, T.J., et al. Aspirin resistance: position paper of the Working Group on aspirin resistance. J Thromb Haemost 3 (2005), 1309–1311.
38. Tantry, U.S., Bliden, K.P., Gurbel, P.A., Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005), 1705–1709.
39. Keating, F.K., Sobel, B.E., Schneider, D.J., Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 92 (2003), 1362–1365.
40. Assert, R., Scherk, G., Bumbure, A., Pirags, V., Schatz, H., Pfeiffer, A.F., Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 44 (2001), 188–195.
41. Vaidyula, V.R., Boden, G., Rao, A.K., Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17 (2006), 577–585.
42. 2+-ATPases in muscle and heart. J Biol Chem 272 (1997), 23696–23702.
43. Ferreira, I.A., Eybrechts, K.L., Mocking, A.I., Kroner, C., Akkerman, J.W., IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 279 (2004), 3254–3264.
44. Kario, K., Matsuo, T., Kobayashi, H., Matsuo, M., Sakata, T., Miyata, T., Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15 (1995), 1114–1120.
45. Winocour, P.D., Platelet turnover in advanced diabetes. Eur J Clin Invest 24:Suppl. 1 (1994), 34–37.
46. Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J.L., Ueno, M., Kodali, M., et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 4 (2011), 180–187.
47. Addad, F., Chakroun, T., Elalamy, I., Abderazek, F., Chouchene, S., Dridi, Z., et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol 92 (2010), 296–301.
48. Spectre, G., Arnetz, L., Östenson, C.G., Brismar, K., Li, N., Hjemdahl, P., Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 106 (2011), 491–499.
49. Gurbel, P.A., Bliden, K.P., DiChiara, J., Newcomer, J., Weng, W., Neerchal, N.K., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007), 3156–3164.
50. DiChiara, J., Bliden, K.P., Tantry, U.S., Hamed, M.S., Antonino, M.J., Suarez, T.A., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56 (2007), 3014–3019.
51. Bethel, M.A., Harrison, P., Sourij, H., Sun, Y., Tucker, L., Kennedy, I., et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Diabet Med 33 (2016), 224–230.
52. Dillinger, J.G., Drissa, A., Sideris, G., Bal dit Sollier, C., Voicu, S., Manzo Silberman, S., et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 164 (2012), 600–606.
53. Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 119 (2012), 3595–3603.
54. ETDRS Investigators, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268 (1992), 1292–1300.
55. Côté R., Battista, R.N., Abrahamowicz, M., Langlois, Y., Bourque, F., Mackey, A., Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing: The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 123 (1995), 649–655.
56. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350 (2004), 114–124.
57. Catalano, M., Born, G., Peto, R., Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261 (2007), 276–284.
58. Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56 (2007), 2382–2391.
59. Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296 (1988), 313–316.
60. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998), 1755–1762.
61. The Medical Research Council's General Practice Research Framework, Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998), 233–241.
62. Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
63. Ogawa, H., Nakayama, M., Morimoto, T., Uemura, S., Kanauchi, M., Doi, N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
64. Fowkes, F.G., Price, J.F., Stewart, M.C., Butcher, I., Leng, G.C., Pell, A.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303 (2010), 841–848.
65. Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
66. Bartolucci, A.A., Tendera, M., Howard, G., Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 107 (2011), 1796–1801.
67. Raju, N., Sobieraj-Teague, M., Hirsh, J., O'Donnell, M., Eikelboom, J., Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 124 (2011), 621–629.
68. Berger, J.S., Lala, A., Krantz, M.J., Baker, G.S., Hiatt, W.R., Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 162 (2011), 115–124.
69. Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Erqou, S., Sattar, N., et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 172 (2012), 209–216.
70. Xie, M., Shan, Z., Zhang, Y., Chen, S., Yang, W., Bao, W., et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One, 9, 2014, e90286.
71. Raju, N., Sobieraj-Teague, M., Bosch, J., Eikelboom, J.W., Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med 129 (2016), e35–e36.
72. Guirguis-Blake, J.M., Evans, C.V., Senger, C.A., O'Connor, E.A., Whitlock, E.P., Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 804–813.
73. Whitlock, E.P., Burda, B.U., Williams, S.B., Guirguis-Blake, J.M., Evans, C.V., Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 826–835.
74. Vandvik, P.O., Lincoff, A.M., Gore, J.M., Gutterman, D.D., Sonnenberg, F.A., Alonso-Coello, P., et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), 637–668.
75. Sutcliffe, P., Connock, M., Gurung, T., Freeman, K., Johnson, S., Kandala, N.B., et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess 17 (2013), 1–253.
76. Okada, S., Morimoto, T., Ogawa, H., Sakuma, M., Soejima, H., Nakayama, M., et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J 77 (2013), 3023–3028.
77. Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
78. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
79. Gaede, P., Lund-Andersen, H., Parving, H.H., Pedersen, O., Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008), 580–591.
80. Saito, Y., Okada, S., Ogawa, H., Soejima, H., Sakuma, M., Nakayama, M., et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 135 (2017), 659–670.
81. Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 87 (2010), 211–218.
82. Stavrakis, S., Stoner, J.A., Azar, M., Wayangankar, S., Thadani, U., Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci 341 (2011), 1–9.
83. Butalia, S., Leung, A.A., Ghali, W.A., Rabi, D.M., Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol, 10, 2011, 25.
84. Kunutsor, S.K., Seidu, S., Khunti, K., Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 34 (2017), 316–327.
85. Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
86. Halvorsen, S., Andreotti, F., ten Berg, J.M., Cattaneo, M., Coccheri, S., Marchioli, R., et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 64 (2014), 319–327.
87. Association, A.D., Standards of medical care in diabetes–2016. Diabetes Care 39 (2016), 60–71.
88. Cardiovascular disease and risk management. Diabetes Care 39 (2016), 60–71.
89. Fox, C.S., Golden, S.H., Anderson, C., Bray, G.A., Burke, L.E., de Boer, I.H., et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132 (2015), 691–718.
90. Bibbins-Domingo, K., U.S. Preventive Services Task Force, Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164 (2016), 836–845.
91. Patrono, C., The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 66 (2015), 74–85.
92. Chubak, J., Whitlock, E.P., Williams, S.B., Kamineni, A., Burda, B.U., Buist, D.S., et al. Aspirin for the prevention of cancer incidence and mortality: sstematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 814–825.
93. Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B., Gibbons, R., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl. 2 (2014), S49–S73.
94. Capodanno, D., Angiolillo, D.J., Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 134 (2016), 1579–1594.
95. Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., et al. In vivo platelet activation and aspirin responsiveness in type 1 diabetes. Diabetes 65 (2016), 503–509.
96. De Berardis, G., Sacco, M., Evangelista, V., Filippi, A., Giorda, C.B., Rognoni, G., et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials, 8, 2007, 21.